TY - JOUR
T1 - Biologicals for pediatric patients with atopic dermatitis
T2 - practical challenges and knowledge gaps
AU - van der Rijst, Lisa P.
AU - van Royen-Kerkhof, Annet
AU - Pasmans, Suzanne G.M.A.
AU - Schappin, Renske
AU - de Bruin-Weller, Marjolein S.
AU - de Graaf, Marlies
N1 - Funding Information:
This work was not supported by funding.
Publisher Copyright:
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
PY - 2023/12
Y1 - 2023/12
N2 - Biologicals are becoming increasingly important in the therapeutic landscape of pediatric patients with moderate-to-severe atopic dermatitis (AD). Currently, dupilumab and tralokinumab are registered for the treatment of moderate-to-severe AD, and novel biologicals are expected to follow. Dupilumab was the first biological registered for AD in pediatric patients and was recently approved for patients aged six months to five years. Current and emerging biologicals may address the unmet need for effective and safe treatment options for pediatric AD patients, however, little is known about the practical implementation of biologicals in infants and preschoolers (aged <6 years), including the timing of treatment initiation, discontinuation, and long-term administration of the subcutaneous injections. Currently, only a small number of biologicals are approved for the treatment of infants and preschoolers for other inflammatory diseases. Consequently, data on the practical implementation of biological treatment remain scarce. In addition, long-term effects, impact on co-morbidities, and impact on live-accentuated vaccination are still unknown. With the introduction of biologicals for AD from the age of six months, potential challenges within the implementation of biologicals may arise. Therefore, we aim to discuss current practical challenges and knowledge gaps of the treatment with biologicals in infants and preschoolers with AD.
AB - Biologicals are becoming increasingly important in the therapeutic landscape of pediatric patients with moderate-to-severe atopic dermatitis (AD). Currently, dupilumab and tralokinumab are registered for the treatment of moderate-to-severe AD, and novel biologicals are expected to follow. Dupilumab was the first biological registered for AD in pediatric patients and was recently approved for patients aged six months to five years. Current and emerging biologicals may address the unmet need for effective and safe treatment options for pediatric AD patients, however, little is known about the practical implementation of biologicals in infants and preschoolers (aged <6 years), including the timing of treatment initiation, discontinuation, and long-term administration of the subcutaneous injections. Currently, only a small number of biologicals are approved for the treatment of infants and preschoolers for other inflammatory diseases. Consequently, data on the practical implementation of biological treatment remain scarce. In addition, long-term effects, impact on co-morbidities, and impact on live-accentuated vaccination are still unknown. With the introduction of biologicals for AD from the age of six months, potential challenges within the implementation of biologicals may arise. Therefore, we aim to discuss current practical challenges and knowledge gaps of the treatment with biologicals in infants and preschoolers with AD.
KW - Atopic dermatitis
KW - biological therapy
KW - children
KW - immunomodulating therapy
KW - pediatric dermatology
UR - http://www.scopus.com/inward/record.url?scp=85169650944&partnerID=8YFLogxK
U2 - 10.1080/09546634.2023.2254567
DO - 10.1080/09546634.2023.2254567
M3 - Comment/Letter to the editor
C2 - 37664977
AN - SCOPUS:85169650944
SN - 0954-6634
VL - 34
JO - Journal of Dermatological Treatment
JF - Journal of Dermatological Treatment
IS - 1
M1 - 2254567
ER -